Lonza Group AG Return on Equity

Lonza Group AG (LZAGF) currently reports a ROE of 7.67%. That is above the Healthcare sector average of -100.59%. Use the charts on this page to explore Lonza Group AG's ROE history and peer comparisons.

Lonza Group AG's ROE of 7.67% is higher than the Healthcare sector average of -100.59%. That is roughly 107.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Lonza Group AG's current 7.67% should be judged against Healthcare norms (sector average: -100.59%) and against LZAGF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 7.67%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Lonza Group AG, and consider following LZAGF for alerts when major investors trade the stock.

Lonza Group AG is classified in the Healthcare sector. On ROE, it currently shows 7.67% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LZAGF with unrelated industries.